Pfizer (PFE) stock prices updated...
 

Pfizer stock price, PFE

Pfizer stock chart:



Pfizer close price: 33.01

Stock price forecast:

UP TO +0.61%
Target: 33.21

Total forecasts: 81
Reached: 47 (58.02%)

Total Win: 25.73 (75.54%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90824757.32%25.730.92%1,179.5324.122.04%49.851.80%
30301653.33%6.310.62%462.820.620.13%6.930.69%
1415213.33%0.710.14%429.18-0.01-0.00%0.700.14%
7800.00%0.000.00%264.080.000.00%0.000.00%

Showing 1-10 of 580 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-05-2333.0133.220000-00-00
2017-05-2233.0133.30000-00-00
2017-05-2133.0133.30000-00-00
2017-05-2033.0133.410000-00-00
2017-05-1933.0133.390000-00-00
2017-05-1833.0133.240000-00-00
2017-05-1733.0133.460000-00-00
2017-05-1633.0133.390000-00-00
2017-05-1533.0132.950000-00-00
2017-05-1433.0132.860000-00-00

Pfizer latest news:


  • 05/17/2017 10:01:27

    Most Dow stocks are below their 50-day moving averages

    As the Dow Jones Industrial Average slips Wednesday below its 50-day moving average (MA), which many technicians use to define the short-term trend, 17 of its 30 components are also below their respective 50-day MAs. Of that total, shares of Boeing Co. and Merck & Co. Inc. are below their 50-day MAs after closing above them on Tuesday, while UnitedHealth Group Inc.'s stock was above its 50-day MA as recently as Monday. Of that total, Pfizer Inc. , Chevron Corp. , General Electric Co. , Intel Corp. , Verizon Communications Inc. , International Business Machines Corp. , Merck and Procter & Gamble Co. were also below their respective 200-day MAs, which are viewed as dividing lines between longer-term uptrends and downtrends. Exxon Mobil Corp.'s stock was below its 200-day MA, but was still above its 50-day MA. The Dow was down 237 points at 20743, below the 50-day MA at 20,783, but well above the 200-day MA at 19,547.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/10/2017 15:18:02

    Sangamo shares jump on Pfizer collaboration, quarterly results

    Sangamo Therapeutics Inc. shares surged after the gene therapy company reported a narrower-than-expected loss for the quarter and a collaboration with pharmaceutical giant Pfizer Inc. . Sangamo shares jumped 42% to $6.15 after hours. The company reported a first-quarter loss of 23 cents a share on revenue of $3.4 million. Analysts surveyed by FactSet had estimated a loss of 28 cents a share on revenue of $4 million. Separately, Sangamo said it will receive a $70 million upfront payment from Pfizer for a development and manufacturing collaboration for a hemophilia A treatment. Sangamo said it was eligible for up to $450 million in milestone payments under the deal.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/08/2017 10:37:31

    BRIEF-Pfizer says multi-year extension of collaboration with Bill & Melinda Gates Foundation, Children's Investment Fund Foundation

    * Co, the Bill & Melinda Gates Foundation, Children's Investment Fund Foundation announced multi-year extension of collaboration

  • 05/02/2017 11:07:48

    Pfizer beats 1Q profit forecasts, but sales slip

    Pfizer beat Wall Street's expectations for first-quarter profit, thanks to reduced spending on operations and legal and other costs, along with strong sales of key new drugs and longtime blockbuster pain treatment Lyrica

  • 05/02/2017 10:58:09

    Prescription for growth at Pfizer? Analysts say deals

    (Reuters) - Pfizer Inc posted basically flat first-quarter earnings, prompting suggestions that the largest U.S. drugmaker needs to do deals in order to improve its growth prospects.

  • 04/19/2017 14:03:02

    Pfizer is latest to get Justice Department subpoena in intravenous saline investigation

    Pfizer Inc. has been subpoenaed by the Justice Department as part of an antitrust investigation into intravenous saline sales practices, requests that it is "evaluating," the company said Wednesday. Saline is a salt water solution that's widely used in the medical system. The shortage caught attention in recent years, with manufacturers claiming they just couldn't keep up with demand. Prices rose 200% to 300% since the 2013 shortage, according to a letter sent by four senators to the Federal Trade Commission in late October 2015. Pfizer acquired Hospira, one of three main saline manufacturers, in September 2015. Wednesday's news follows a Tuesday disclosure by ICU Medical , which Pfizer completed a sale of its infusion therapy assets to in early February, that it had been subpoenaed in connection with an investigation. ICU Medical said it has also had a request from the New York Attorney General for information on its IV solution sales practices, and that "both of these investigations relate primarily to time periods prior to the Company's ownership." The subpoena called for "documents regarding the manufacturing, selling, pricing and shortages of intravenous ("IV") solutions, including saline, sold by the Company and communications with competitors regarding the same," ICU Medical said. Pfizer said in a March 16 financial filing that it was being sued in an Illinois district court for allegedly artificially raising prices of IV saline solution, with the lawsuit aiming for class action status. On Friday, another company, Baxter International Inc. , said that one of its employees had received agrand jury subpoena as part of an investigation into its saline sales practices. Pfizer shares slumped 0.6% in Wednesday afternoon trade. Shares have risen 6.2% over the last three months, compared with a 3.3% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/04/2017 07:08:41

    Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs

    Onconova Therapeutics Inc. stock surged as much as 18% in premarket trade Tuesday after the company said its two cancer drugs had positive pre-clinical results. Onconova shares were valued at $3.01 as of Monday's close. One drug, ON 123300, was found in a model to work as well as Pfizer Inc.'s Ibrance, and could lead to less infection susceptibility, the company said. The other drug, ON 150030, showed promising results in relapsed and refractory Acute Myeloid Leukemia, the company said. Both results were presented on Monday at the American Association for Cancer Research's annual meeting. Onconova shares have surged 30.3% over the last three months, compared with a 3.9% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Pharmerica CorporationPMC | PHH CorpPHH | Philip Morris International IncPM | Philippine Long Distance Telephone CompanyPHI | Phillips 66PSX-0.55% | Phillips 66 Partners LPPSXP | Phoenix CompaniesPFX | Phoenix CompaniesPNX | Phoenix New Media LimitedFENG | Physicians Realty TrustDOC |